Tuesday, October 12
7:00 – 4:30 pm
7:30 – 8:10 am
Breakfast with The Rock Stars
Adam Gazzaley, Founder & Executive Director, Neuroscape
Ralph Snyderman, MD, Chancellor Emeritus, Duke University
8:10 – 8:15 am
Sara Jane Demy, CEO & founder, Demy-Colton
8:00 – 5:00 pm
8:15 – 9:30 am
Opening Plenary Session
The Tsunami is Underway & Healthcare will Never be the Same: A Look at Healthcare in the Modern Tech Era
While technological and digital advances are poised to impact every facet of healthcare – personalized diagnostics, precision therapeutics, artificial intelligence, new clinical care models, patient influence, population outcomes and consumer driven care – the rate and pace of this change is staggering and will have differing investment timelines and opportunities. Hear a leading expert paint the “Big Picture" of the transformation that is underway and its future implications.
Presenter: Ralph Snyderman, MD, Chancellor Emeritus, Duke University
9:30 – 9:45 am
9:45 – 12:00 pm
9:45 – 10:30 am
Metabesity: A Healthcare Burden on the Rise
Metabesity, a constellation of the major chronic diseases affecting an ageing population, is on the rise globally. Its societal burden, a mix of chronic, non-communicable diseases, is staggering and growing.
Kevin McRaith, President & CEO, WellDoc (Invited)
Leila Pirhaji, CEO, ReviveMed (Invited)
Michael Wolfe, CMO, Lobesity LLC
10:30 – 11:15 pm
Dementia: A Tsunami Underway
Finding a treatment for dementia and Alzheimer’s has eluded the best biopharma companies to date. Recent research indicates that inflammation plays a part in dementia and Alzheimer’s while new digital entrants are looking at new ways of identifying this disease early and interrupting the process.
Phyllis Ferrell, VP, Global Alzheimer’s Disease Platform Team, Eli Lilly and Company
Howard Fillit, Executive Director & CSO, The Alzheimer’s Drug Discovery Foundation
Angus Grant, CEO, Dementia Discovery Fund
11:15 – 12:00 pm
What’s Next in Gene Editing
Genome editing has the potential to change the lives of millions of people. As research continues and the suite of gene editing tools and techniques expand, therapeutics and cures are now possible for diseases that were previously untreatable and often fatal. Like any profoundly powerful technology, genome editing has the potential for abuse and downstream consequences that raise new questions both ethical and scientific for our industry and society as a whole.
Mike Rice, Principal, Cello Health BioConsulting
Alexander Macrae, President & CEO, Sangamo Therapeutics, Inc. (Invited)
Bing Wang, Co-founder & CEO, Refuge Biotech
12:00 – 1:45 pm
Healthcare for All: Pipe Dream or in the Pipeline?
How can we optimize our innovation ecosystem, so that it serves the most good for the greatest amount of people? How do we simultaneously produce the best and most accessible innovation? With the developed world dedicating increasingly more resources to new health solutions, questions of access and equitability are relevant to both the mission of better health for all, as well as to the global business opportunities.
Trent Haywood, Founder, Knowality
2:00 – 4:00 pm
2:00 – 2:45 pm
The Future of Aging: Vitality vs Disease
Nir Barzilai, Founder, CohBar, Inc. (Invited)
Mylea Charvat, CEO, Savonix, Inc.
Christina Jenkins, Partner, Longevity & Health Aging Fund, Portfolia
Brian Kennedy, Director, Centre for Healthy Ageing; Professor Depts. of Biochemistry and Physiology, National University of Singapore
Michael West, CEO, AgeX Therapeutics (Invited)
2:45 – 3:30 pm
Bioelectronic Medicine: Healthcare Innovation from a Wall Socket Near You
Electricity as a therapeutic has been used to re-right heartbeats, to stimulate nerves, neurochemicals and cellular regeneration. Today there is a surge of new medical devices being developed and new bioelectrical treatments for everything from treating a host of CNS diseases to cancer and diabetes. Join our panel of experts as we discuss recent research, the favorable regulatory environment and new business models around the electrifying new wave of potential for bioelectrical therapeutics.
Beth Rogozinski, CEO, Signal2Health
Paolo Cassano, Co-founder, Niraxx
Imran Eba, Partner, Action Potential Venture Capital
Jennifer Ernst, CEO & Co-founder, Tivic Health
Brad Schmidt, CEO, Panaxium
3:30 – 4:15 pm
Direct to Consumer Marketing – An Indication of the Future
On these sites, people self-diagnose and select the drug they want, then enter some personal health and credit information. A doctor then assesses their choice, with no in-person consultation. If approved, the medicine arrives in the mail days or weeks later. The sites invert the usual practice of medicine by turning the act of prescribing drugs into a service. Instead of doctors making diagnoses and then suggesting treatments, patients request drugs and physicians serve largely as gatekeepers card information.
Tim Opler, Partner & Co-founder, Torreya
Mitchell Steiner, President & CEO, Veru
4:15 – 5:00 pm
Brain-Machine Interface – A Two-Way Street
Matt Angle, CEO, Paradromics (Invited)
Kamran Fallahpour, Founder & Chief Science Officer, Vital Neuro, Inc.
Meron Gribetz, CEO, Inner Cosmos
Owen Phillips, CEO, BrainKey
Nanea Reves, CEO & Co-founder, Tripp (Invited)
5:00 – 5:45 pm
Meet the New Disrupters Who are Changing Healthcare Today
Jacob Becraft, Co-founder & CEO, Strand Therapeutics
Brent Vaughan, CEO, Cognoa
6:00 – 7:30 pm